Table 2.
The Influence of Haplotypes on Survival in Osteosarcoma Patients
| Event-free survival | Overall survival | |||||
|---|---|---|---|---|---|---|
| Gene | Haplotype | Estimated frequency | HR (95 % CI) | pa | HR (95 % CI) | pa |
| REV1b | CAT | 0.45 | Reference | Reference | ||
| TGT | 0.18 | 1.58 (0.83–3.00) | 0.161 | 1.91 (0.98–3.71) | 0.058 | |
| CGC | 0.14 | 1.49 (0.77–2.91) | 0.239 | 1.20 (0.59–2.44) | 0.624 | |
| CGT | 0.11 | 0.73 (0.31–1.71) | 0.465 | 0.54 (0.21–1.38) | 0.197 | |
| REV3Lc | TGA | 0.65 | Reference | Reference | ||
| TAA | 0.14 | 1.11 (0.62–2.00) | 0.731 | 1.61 (0.85–3.05) | 0.142 | |
| CGG | 0.08 | 2.98 (0.96–9.26) | 0.059 | 3.27 (1.20–8.85) | 0.020 | |
| TGG | 0.06 | 0.67 (0.24–1.86) | 0.446 | 0.79 (0.21–2.96) | 0.715 | |
a
p less than 0.010 was considered statistically significant after correction for multiple comparisons; bThe SNPs are ordered from the 5′- to 3′-end as follows: rs3087403, rs3087386, and rs3087399; cThe SNPs are ordered from the 5′- to 3′-end as follows: rs462779, rs3204953, and rs465646.
CI, confidence interval; HR, hazard ratio.